Key Takeaways
- EBITDA more than doubled to ₹31.5 crore, driven by volume growth in both Distribution and Manufacturing, even as global chemical prices melted down.
- Distribution margins rose over 60% YoY despite the price environment, helped by consistent principal support and a stabilizing U.S. Oil & Gas sector from January 2024.
- Manufacturing EBITDA jumped 70% YoY, fueled by an export push for Acrylamide, new customer additions in Europe, and a pickup in Acrylamide Solid sales as Chinese dumping eased.
- New product revenue is a next-year story: Polyacrylamide Solid R&D will complete this fiscal, but commercialization and meaningful revenue are expected only in FY26, while the Specialty Chemicals project remains in the clearance phase.
- What to watch next quarter: Whether the domestic demand pickup and stabilizing chemical prices translate into sustained volume growth, and any concrete timeline on Polyacrylamide Solid plant setup.
Manufacturing: The Volume Engine
- Acrylamide export push paid off: Sales volume increased materially due to a deliberate focus on export markets, adding new customers, expanding European reach, and preregistration with Turkey, which helped offset subdued domestic conditions.
- Acrylamide Solid turned a corner: Sales started picking up from January 2024 as Chinese producers began exporting at realistic prices instead of dumping, making the company competitive in the Indian market again.
- NMA orders became regular: N-Methylol Acrylamide sales improved considerably after receiving validation and commercial orders from key domestic customers, and the company now holds a majority share of volume from leading players.
- Acrylonitrile price stability helped: The raw material dropped from ~$1400 to a $950-$1000 bottom in July, then stayed range-bound at $1200-$1300 in H2, which allowed better procurement planning and boosted both sales volume and profitability on manufactured products.
- Morbi ceramic market stayed weak: The tile cluster struggled all year with high gas prices, subdued export demand, and Red Sea logistics disruptions hitting Middle East shipments, while small local units mushroomed with low-overhead competition.
- Competition is temporary: Small players importing Chinese powder and undercutting on price tend to appear when raw material costs fall, but they exit quickly once the market stabilizes, so the company avoids price wars and focuses on loyal, consistent customers.
Ambarish Daga: "We don't like to get involved in any unfair price policies or wars, as I mentioned. So, these are suppliers which keep mushrooming from time to time when the raw material cost is decreasing because there are other raw materials also and then they just come out of business very soon once the market stabilizes. So, it's more of a temporary phenomenon."
Distribution: Margin Resilience in a Price Downturn
- Margins grew over 60% YoY even as global chemical prices melted down, because the company ramped up sales quantities, managed inventory well, and received consistent volume allocations and timely shipments from principals for key products like Resorcinol, Isophthalic Acid, and Ethylamine.
- U.S. Oil & Gas exports stabilized: Demand was subdued through most of the year but began steadying from January 2024, leading to much better Q4 sales compared to the previous quarter and setting up consistent volumes going forward.
- Logistics disruption is a double-edged sword: Red Sea issues tripled freight costs during the March quarter, but the company's stock-and-sales model lets it service customers who struggle to get import material on time, creating an opportunity for higher volumes with good margins.
- Freight cost pass-through varies by product: For Acrylamide Solid, container freight is a competitive factor between India and China regardless of supplier; for Acrylamide Liquid, freight matters much more because the product cost is roughly half that of solid, making freight a much larger share of total cost and rendering some markets unviable when rates spike.
- Domestic demand is now picking up: After a long subdued period, products like Ethylamine, Isophthalic Acid, and Resorcinol are expected to deliver additional volumes, supported by an expanded sales team and new product additions to the Distribution portfolio.
Ambarish Daga: "As distributors, we are product specialists. We seed the market with the products, we educate the customers, we also provide the valuable feedback to these manufacturers giving the perspective of the product and how much is the quantity, et cetera for the various products that we deal in."
New Projects: Progress Without Timelines
- Polyacrylamide Solid R&D is the critical path: The soft technology (recipe and process) is finalized, but the company is still working on finalizing equipment (hard technology), evaluating both domestic and import options to achieve optimum efficiency and global competitiveness.
- Plant setup can move fast once R&D locks: Space is already earmarked in the existing Jhagadia plant with the building ready, and once the equipment decision is made, setup should take 6 to 9 months, but R&D completion is now expected only by fiscal year-end.
- Revenue is a FY26 story: Management is hopeful of starting to generate revenue from Polyacrylamide Solid in FY26, and most revenue from new products will crystallize only next year, not this year.
- Market access advantage is real: The company is already a distributor for Polyacrylamide Solid with good product and market knowledge, which should help it gain market traction quickly and expedite customer approvals once the manufactured product launches.
- Specialty Chemicals project is inching forward: Environment clearance application is progressing, land parcels are shortlisted for a 20-acre acquisition, and the investment is roughly estimated at ₹20-30 crores, but the project remains in the pipeline with no firm timeline.
- Toll manufacturing discussions are ongoing: Talks with U.S. and European customers are moving in the right direction, but the process is lengthy (intention, technology discussions, capability assessment, raw material availability) and bound by secrecy clauses, so no major update is available.
- Capex is staggered, not lumpy: The entire ₹35-40 crore capex envelope may not be required in the coming year; spending depends on how clearances and other activities progress, and the company has substantial reserves with no current need for a fund raise.
Ambarish Daga: "Now R&D, if you understand does take a long time and one part of the R&D is to manufacture the product. The other part is to actually manufacture it in the most efficient way so that you know, we are very competitive globally for this product. So that is what we are striving for, to achieve the optimum efficiency levels and as soon as we are certain about that, we will definitely start with the next steps in this direction."
Geopolitical Tailwinds: China+1 and Europe+1
- Europe+1 is opening doors: European companies are actively trying to buy from non-European sources as a procurement hedging strategy, which is helping Black Rose penetrate new customers even though overall European demand remains sluggish.
- The European base is tiny, so the runway is long: Black Rose's share of the European market is very small, and most customers are large multinationals starting with small allocations that are gradually increasing, leaving substantial scope for additional volumes.
- Customer acquisition is slow by design: Adding new customers involves product validation, ordering processes, and trials, and the company prioritizes working with partners on the same principles of loyalty and partnership rather than chasing volume for its own sake.
- China+1 is also contributing: The broader shift away from Chinese supply is helping, though management did not quantify the specific impact separately from the Europe+1 dynamic.
Ambarish Daga: "We are able to get good traction and we are able to penetrate into new customers because of the policies of these companies to basically hedge their procurement and distribute it amongst European and non-European suppliers."
Margins & Outlook
- Chemical prices have bottomed out: Prices are now stable and firming up, and management hopes the Chinese economy picks up (some signs appeared over the last month), which would push prices higher and positively affect the global chemical sector.
- Margin headroom exists on multiple fronts: The still-stagnant Chinese market, logistics lock-jams that create service opportunities, and scope for much higher volumes all point to room for both volume growth and sustainable margin expansion, though management declined to give a specific ceiling or target.
- Logistics costs should ease gradually: Freight costs are coming down from the 3x spike seen during the March quarter but remain volatile, and management expects some improvement going forward.
- Growth this year comes from the existing base: Revenue expansion is expected from the existing manufacturing business, conscious addition of new products and new customers in Distribution, and new geographic spread in both segments, not from the new projects.
- Management will not quantify the outlook: Citing too many variables and uncertainty, the company declined to give a specific revenue or volume growth number for the year, though it sees demand picking up and supplier support helping increase volumes.
Ambarish Daga: "What we learnt over the last few years is that uncertainty is the only thing which is certain."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Polyacrylamide Solid R&D completion | R&D activity to be completed | Within this fiscal year (FY25) |
| Polyacrylamide Solid plant setup | 6-9 months from process start | Begins after R&D completion; no start date given |
| Polyacrylamide Solid revenue start | Hopeful to start generating revenue | FY26 |
| Specialty Chemicals environment clearance | Application progressing; land parcels shortlisted | No timeline given |
| Capacity increases for NMA and Acrylamide Solid | Will take a call when consistent sales hit a threshold | No threshold or date specified |
| Capex deployment | ₹35-40 crore total envelope; may not all be required in the coming year | Depends on clearances and activity progress |
Key Metrics
| Metric | Q4 FY24 |
|---|---|
| Revenue from operations | Steady, maintained despite global chemical price meltdown; sales quantities ramped up |
| Standalone EBITDA | ₹31.5 cr, more than doubled YoY; EBITDA percentage more than doubled |
| Standalone EBITDA growth | ~125% YoY |
| EPS (full year FY24) | ₹4.01 |
| Total sales volume growth | ~20% YoY |
| Distribution revenue share | 68% of total top line |
| Distribution margin growth | More than 60% YoY |
| Manufacturing EBITDA growth | 70% YoY |
| Top 5 products revenue share | 77% of distribution top line |
| Top 5 products profit share | 71% of distribution bottom line |
| Acrylamide export share | 65% of Acrylamide production exported |
| Acrylamide Liquid capacity utilization | 70%–80% in Q4 |
| Acrylonitrile price range (H2 FY24) | $1,200–$1,300 per metric ton, range-bound in H2 |
| Logistics cost increase (Red Sea impact) | 3-fold increase during the quarter up to March |